CA3118881A1 - Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor - Google Patents

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

Info

Publication number
CA3118881A1
CA3118881A1 CA3118881A CA3118881A CA3118881A1 CA 3118881 A1 CA3118881 A1 CA 3118881A1 CA 3118881 A CA3118881 A CA 3118881A CA 3118881 A CA3118881 A CA 3118881A CA 3118881 A1 CA3118881 A1 CA 3118881A1
Authority
CA
Canada
Prior art keywords
cells
transplantation
transplantation rejection
composition
transplant rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3118881A
Other languages
English (en)
French (fr)
Inventor
Mi-La Cho
Dong-Yun Shin
Jong-Young Choi
Chul-Woo Yang
Sung-Hwan Park
Seon-Yeong Lee
Min-Jung PAKR
Joo-Yeon Jhun
Se-Young Kim
Hyeon-Beom Seo
Jae-Yoon RYU
Keun-Hyung CHO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Catholic University of Korea
Original Assignee
Industry Academic Cooperation Foundation of Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Catholic University of Korea filed Critical Industry Academic Cooperation Foundation of Catholic University of Korea
Publication of CA3118881A1 publication Critical patent/CA3118881A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3118881A 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor Pending CA3118881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180136107A KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
KR10-2018-0136107 2018-11-07
PCT/KR2019/015055 WO2020096371A1 (ko) 2018-11-07 2019-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Publications (1)

Publication Number Publication Date
CA3118881A1 true CA3118881A1 (en) 2020-05-14

Family

ID=70612506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3118881A Pending CA3118881A1 (en) 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

Country Status (8)

Country Link
US (1) US11969397B2 (https=)
EP (1) EP3878443A4 (https=)
JP (1) JP7470683B2 (https=)
KR (1) KR102147802B1 (https=)
CN (1) CN113194936A (https=)
AU (1) AU2019377749B2 (https=)
CA (1) CA3118881A1 (https=)
WO (1) WO2020096371A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554139B2 (en) * 2019-05-17 2023-01-17 Tolerogenixx Gmbh MIC therapy for specific immunosuppression in transplantation
CN115843745A (zh) * 2021-09-26 2023-03-28 泰州迈博太科药业有限公司 一种人源化肠炎小鼠模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US10369121B2 (en) 2013-08-23 2019-08-06 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
JP6462002B2 (ja) 2014-04-29 2019-01-30 ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション 免疫疾患治療効果を有する新規化合物およびその使用
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101613371B1 (ko) 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180038355A (ko) 2016-10-06 2018-04-16 서울과학기술대학교 산학협력단 탄성 및 기계적 물성이 우수한 탄성 고분자-세라믹 하이브리드 필름 및 이의 제조방법
KR20190045513A (ko) 2017-10-24 2019-05-03 가톨릭대학교 산학협력단 Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
US20220031637A1 (en) 2022-02-03
EP3878443A4 (en) 2022-08-24
WO2020096371A1 (ko) 2020-05-14
US11969397B2 (en) 2024-04-30
JP7470683B2 (ja) 2024-04-18
EP3878443A1 (en) 2021-09-15
AU2019377749B2 (en) 2024-10-03
AU2019377749A2 (en) 2021-06-03
CN113194936A (zh) 2021-07-30
KR102147802B1 (ko) 2020-08-25
KR20200052743A (ko) 2020-05-15
JP2022513590A (ja) 2022-02-09
AU2019377749A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Van Sandwijk et al. Immunosuppressive drugs after solid organ transplantation
KR101578591B1 (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Kim et al. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease
EP1789034A1 (en) Compounds with diphenoyl -structure for the treatment of immune diseases
Khorshid et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.
CA3118881A1 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
JP2020527044A (ja) ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
Guo et al. Harnessing the dual immunomodulatory function of myeloid-derived suppressor cells to reshape the inflammatory microenvironment for osteoarthritis therapy
Gu et al. The effect of asarinin on toll-like pathway in rats after cardiac allograft implantation
Stanojlovic et al. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival
Konishi et al. Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model
Kinugasa et al. Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model
WO2004052305A2 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
JP7010817B2 (ja) 組織損傷の治療に有用な医薬組成物
WO2007141667A2 (en) Immunosuppressive extract of cordyceps sinensis and uses thereof
US20250009817A1 (en) Immunomodulating composition containing gasseri
Liu et al. Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice
WO2001087324A1 (en) Compositions and methods for promoting immunosuppression
KR20130023797A (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
KR102256337B1 (ko) 조직이식을 위한 세포배양액을 포함하는 면역억제제
MX2008014516A (es) Uso de timosina alfa 1 para el tratamiento de enfermedades inmunitarias.
Groeneweg Novel diagnostics and therapeutics to prevent injury in native and transplanted kidneys
WO2025140929A1 (en) Compositions comprising platelet derived extracellular vesicles
JP2025516366A (ja) 同種移植拒絶反応の治療方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241004

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250619

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250619

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251128

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309